The T-cell-redirecting bispecific antibody talquetamab (Talvey®) has shown promising efficacy in patients with relapsed/refractory multiple myeloma (1). Based on its mechanism of action, talquetamab presents with a distinct side effect profile which is clinically well manageable (2). Here, we review the efficacy of talquetamab and discuss the clinical management strategies for its most important adverse events.
Pharma-Sonderreport verantwortet von Janssen-Cilag AG, a Johnson & Johnson company
